PT  - JOURNAL ARTICLE
AU  - Odio, Camila
AU  - Yek, Christina
AU  - Hasund, Chloe M.
AU  - Man, Somnang
AU  - Ly, Piseth
AU  - Nhek, Sreynik
AU  - Chea, Sophana
AU  - Lon, Chanthap
AU  - Voirin, Charlie
AU  - Huy, Rekol
AU  - Leang, Rithea
AU  - Huch, Chea
AU  - Oliveira, L. Fabiano
AU  - Manning, Jessica E.
AU  - Katzelnick, Leah C.
TI  - Immunity to non-dengue flaviviruses impacts dengue virus IgG ELISA specificity in Cambodia
AID  - 10.1101/2023.11.17.23298701
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.17.23298701
4099  - http://medrxiv.org/content/early/2023/11/20/2023.11.17.23298701.short
4100  - http://medrxiv.org/content/early/2023/11/20/2023.11.17.23298701.full
AB  - Seroprevalence studies are the gold standard for disease surveillance, and serology was used to determine eligibility for the first licensed dengue vaccine. However, expanding flavivirus endemicity, co-circulation, and vaccination complicate serology results. Among 713 healthy Cambodian children, a commonly used indirect dengue virus IgG ELISA (PanBio) had a lower specificity than previously reported (94% vs. 100%). Of those with false positive PanBio results, 46% had detectable neutralizing antibodies against other flaviviruses, with the highest frequency against West Nile virus (WNV). Immunity to non-dengue flaviviruses can impact dengue surveillance and potentially pre-vaccine screening efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Intramural Research Program at the National Institute of Allergy and Infectious Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the institutional review boards at the US National Institutes of Health and the National Ethics Committee on Human Research in Cambodia. The guardians of all pediatric participants provided signed informed consent to participate in the study. Between July and August of 2018, 771 children aged 2-9 years living in Kampong Speu, Cambodia were enrolled in a prospective longitudinal cohort (NCT03534245).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.